Chemotherapy for Gastrointestinal Cancer: New Hopes or New Disappointments?

References

• Herskovic A, Martz K, Al-Sarraf M, et al. Intergroup esophageal study: comparison of radiotherapy (RT) to radio-chemotherapy combination: a phase III trial [abstract]. Proc Am Soc Clin Oncol 1991; 10: 135
   Google Scholar
• Sischy B, et al. Interim report of EST 1282 phase III protocol for the evaluation of combined modalities in the treatment of patients with carcinoma of the esophagus, stage I & II [abstract]. Proc Am Soc Clin Oncol 1990; 9: 105
   Google Scholar
• Wils J. Perspectives in the treatment of advanced gastric cancer. Anti-Cancer Drugs 1991; 2: 133–7
   PubMedGoogle Scholar
• Wils J, Klein H O, Wagener D JTh., et al. Sequential high dose methotrexate and 5-fluorouracil combined with doxorubicin: a step ahead in the treatment of advanced gastric cancer. A trial of the EORTC gastro-intestinal (GI) Tract Cooperative Group. J Clin Oncol 1991; 9: 827–31
   PubMed Web of Science ®Google Scholar
• Cruz-Hernándes J, Cervantes A, Belón J, et al. Treatment of stage IV gastric cancer (GC) with a second or third generation chemotherapy [abstract ECCO-6]. Eur J Cancer 1991; S80, Suppl 2
   Google Scholar
• Kelsen D, Atiq O T, Saltz L, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992; 10: 541–8
   PubMed Web of Science ®Google Scholar
• O'Connell M. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric cancer: an old lesson revisited. J Clin Oncol 1992; 10: 515–6
   PubMed Web of Science ®Google Scholar
• Lasser Ph, Rougier Ph, Mahjoubi M, et al. Neoadjuvant chemotherapy (NCT) in locally advanced gastric cancer (LAGC) [abstract ECCO-6]. Eur J Cancer 1991; S71, Suppl 2
   Google Scholar
• Wilke H, Preusser P, Fink U, et al. New developments in the treatment of gastric carcinoma. Semin Oncol 1990; 17: 61–70, Suppl 2
   PubMed Web of Science ®Google Scholar
• Lerner A, Gonin R, Steele G D, Mayer R J. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma results of a phase II trial. J. Clin Oncol 1922; 10: 536–40
   Google Scholar
• Plukker J Th, Mulder N H, Yerschueren R CJ. Combined chemotherapeutic/surgical approach of locally advanced cancer of the cardia and gastric fundus [abstract]. Abstracts of EORTC Symposium on Advances in Gastrointestinal Tract Cancer Research and Treatment 1989; 41
   Google Scholar
• Conroy Th, Wils J, Wagener D JTh., et al (1992) Phase II trial with FEMTX-P in advanced gastric cancer. Feb 4–7, 1992. Frankfurt/Main, 72, Abstracts of International Conference on Biology and Treatment of Gastrointestinal Malignancies
   Google Scholar
• Wils J. Chemotherapy in pancreatic cancer: a rational pursuit?. Anti-Cancer Drugs 1991; 2: 3–10
   PubMedGoogle Scholar
• Blijham G H. Chemotherapy of colorectal cancer. Anti-Cancer Drugs 1991; 2: 233–45
   PubMed Web of Science ®Google Scholar
• Bruckner H W, Motwani B T. Chemotherapy of advanced cancer of the colon and rectum. Semin Oncol 1991; 18: 443–61
   PubMed Web of Science ®Google Scholar
• Advanced Colorectal Cancer Meta-analysis Project. Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896–903
   PubMed Web of Science ®Google Scholar
• Lokich J J. Optimal schedule for 5-fluorouracil chemotherapy. Intermittent bolus or continous infusion?. Am J Clin Oncol 1985; 8: 445–8
   PubMed Web of Science ®Google Scholar
• Carlson R W, Sikic B I. Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med 1983; 99: 823–33
   PubMed Web of Science ®Google Scholar
• Aschele C, Sobrero A F, Guglielmi A, et al. Schedule dependent mechanisms of resistance to 5-fluorouracil in HCT-8 cells [abstract]. Proc Am Soc Cancer Res 1991; 32: 353
   Google Scholar
• Seifert P, Baker L H, Reed M OL, et al. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975; 36: 123–8
   PubMed Web of Science ®Google Scholar
• Lokich J J, Ahlgren J D, Gullo J J, et al. Prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425–32
   PubMed Web of Science ®Google Scholar
• Rougier Ph, Paillot B, Laplanche A, et al. End results of a multicentric randomized trial comparing 5 FU in continuous systemic infusion (CI) to bolus administration (B) in measurable metastatic colorectal cancer (MCC)) [abstract]. Proc Am Soc Clin Oncol 1992; 11: 163
   Google Scholar
• Hansen R, Ryan L, Anderson T, et al. A phase III trial of bolus 5FU versus protracted infusion 5FU+/- cisplatin in metastatic colorectal cancer. An Eastern Cooperative Oncology Group study (EST 2286) [abstract]. Proc Am Soc Clin Oncol 1992; 11: 171
   Google Scholar
• Shah A, MacDonald W, Goldie J, et al. 5-FU infusion in advanced colorectal cancer: a comparison of three dose schedules. Cancer Treat Rep 1985; 69: 739–42
   PubMedGoogle Scholar
• Ardalan B, Singh G, Silberman H. A randomized phase I and II study of short term infusion of high-dose fluorouracil with or without N- (phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancer. J Clin Oncol 1988; 6: 1053–8
   PubMed Web of Science ®Google Scholar
• Odwyer P J, Paul A R, Walczak J, et al. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol 1990; 9: 1497–1503
   Google Scholar
• Hryniuk W M, Figueredo A, Goodyear M. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 1987; 14: 3–11, Suppl 4
   PubMed Web of Science ®Google Scholar
• Díaz-Rubio E, Aranda E, Martin M, et al. Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. Eur J Cancer 1990; 26: 727–9
   PubMed Web of Science ®Google Scholar
• Díaz-Rubio E, Jimeno J, Aranda E, et al. Weekly high-dose infusion of 5-fluorouracil (5-FU) in advanced colorectal cancer [abstract]. Frankfurt 1992; 82, Abstracts of International Conference on Biology and Treatment of Gastrointestinal Malignancies
   Google Scholar
• Conroy T, Adenis A, Brucker P, et al. A prospective randomized trial of protracted infusional 5 FU with allopurinol versus bolus 5 FU and high-dose leucovorin in metastatic colorectal cancers [abstract]. Proc Am Soc Clin Oncol 1992; 11: 162
   Google Scholar
• Martin D S, Stolfi R L, Colofiore J R. Failure of high dose leucovorin to improve therapy with the maximally tolerated dose of 5-fluorouracil: a murine study with clinical relevance?. J Natl Cancer Inst 1988; 80: 496–501
   PubMedGoogle Scholar
• Martin D S, Nord L D, Stolfi R L, et al. Biochemical modulation of 5-fluorouracil (FU): a different biochemical emphasis, (FU) RNA, can produce greater in vivo anticancer efficacy than leucovorin (LV)-FU [abstract]. Proc Am Soc Clin Oncol 1991; 10: 97
   Google Scholar
• Valone F H, Friedman M A, Wittlinger P S, et al. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol 1989; 7: 1427–36
   PubMed Web of Science ®Google Scholar
• Di Constanzo F, Bartolucci R, Calabresi F, et al. Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 1992; 3: 371–6
   PubMedGoogle Scholar
• Ardalan B, Chua L, Tian E, et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991; 9: 625–30
   PubMed Web of Science ®Google Scholar
• Ardalan B, Sridhar K S, Benedetto P, et al. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low- dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. Cancer 1991; 68: 1242–6
   PubMed Web of Science ®Google Scholar
• Ardalan B, Donofrio K, Sridnar K S, et al. Is there hope after 5-FU bolus? A phase II study of short term protracted infusion of high dose 5-fluorouracil (5-FU) with leucovorin (LV), and low dose phosphoacetyl-1-asparctic acid (PALA) in colorectal carcinoma [abstract]. Proc Am Soc Clin Oncol 1992; 11: 186
   Google Scholar
• Gastrointestinal Tumor Study Group. Adjuvant therapy of colon cancer–results of a prospectively randomized trial. N Engl J Med 1985; 312: 1465–72
   PubMed Web of Science ®Google Scholar
• Mansour E, Ryan L, Lerner H, et al. Lack of effectiveness of 5-FU + methyl CCNU as compared to 5-FU for adjuvant therapy in colon cancer [abstract]. Proc Am Soc Clin Oncol 1989; 8: 115
   Google Scholar
• Panettierre F J, Goodman P J, Constanzi J J, et al. Adjuvant therapy in large bowel adenocarcioma: long-term results of a Southwest Oncology Group study. J Clin Oncol 1988; 6: 947–54
   PubMedGoogle Scholar
• Higgins G A, Jr, Amadeo J H, McElhinney J, et al. Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. Cancer 1984; 53: 1–8
   PubMed Web of Science ®Google Scholar
• Abdi E A, Harbora D, Hanson J, et al. Adjuvant chemoimmuno and immunotherapy in stage B2 and C colorectal cancer. Proc Am Soc Clin Oncol 1987; 6: 93
   Google Scholar
• Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Nat Cancer Inst 1988; 80: 30–6
   PubMed Web of Science ®Google Scholar
• Laurie J A, Moertel C G, Fleming T R, et al. Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and 5-fluorouracil. A study of the North Central Cancer Treatment Group (NCCTG) and the Mayo Clinic. J Clin Oncol 1989; 7: 1447–56
   PubMed Web of Science ®Google Scholar
• Moertel C G, Fleming T H, Macdonald J S, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352–8
   PubMed Web of Science ®Google Scholar
• Moertel C, Fleming T, MacDonald J, et al. The Intergroup study of fluorouracil (5-FU) plus levamisole (LEV) and levamisole alone as adjuvant therapy for stage C colon cancer. A final report [abstract]. Proc Am Soc Clin Oncol 1992; 11: 161
   Google Scholar
• Buyse M. (1992) Current status of adjuvant therapy of colon carcinoma [abstract]. Feb 4–7, 1992. Frankfurt/Main, 55, Abstract of International Conference on Biology and Treatment of Gastrointestinal Malignancies
   Google Scholar
• The efficacy and the group C status of levamisole plus 5-fluorouracil for patients with Dukes' C colon cancer. National Cancer Institute (NCI) press release on levamisole Bethesda, MarylandUSA September 26, 1989
   Google Scholar
• Wils J A, Wagener D JTh. Adjuvant treatment of colon cancer. Where to go from here? Ann Oncol 1990; 1: 329–31
   PubMedGoogle Scholar
• National Cancer Institute Clinical Announcement. Adjuvant Therapy of Rectal Cancer. March 14, 1991
   Google Scholar
• Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Nat Cancer Inst 1988; 80: 21–9
   PubMed Web of Science ®Google Scholar
• Douglass H O, Jr, Moertel C G, Mayer R J, et al. Survival after postoperative combination treatment of rectal cancer. N Engl J Med 1986; 315: 1294–5
   PubMed Web of Science ®Google Scholar
• Krook J E, Moertel C G, Gunderson L L, et al. Effective surgical adjuvant therapy for high-risk rectal cancer. New Engl J Med 1991; 324: 709–15
   PubMed Web of Science ®Google Scholar
• Mansour E G, Lefkopoulou M, Johnson R, Douglass H, Jr. A comparison of post-operative adjuvant chemotherapy, radiotherapy or combination therapy in potentially curable resectable rectal carcinoma. An ECOG study EST 4276 [abstract]. Proc Am Soc Clin Oncol 1991; 10: 154
   Google Scholar
• O'Connell M, Wieand H, Krook J, et al. Lack of value for methyl-CCNU(MeCCNU) as a component of effective rectal cancer surgical adjuvant treatment: interim analysis of intergroup protocol 86-47-51 [abstract]. Proc Am Soc Clin Oncol 1991; 10: 134
   Google Scholar
• Gastrointestinal Tumor Study Group. Radiation therapy and 5-fluorouracil (5-FU) with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 1992; 10: 549–57
   PubMed Web of Science ®Google Scholar
• Wils J, Wagener D JTh. Combined modality adjuvant treatment of high-risk rectal cancer: a treatment of choice or a choice of treatment?. Ann Oncol 1992; 3: 197–9
   PubMedGoogle Scholar